Companies like Atai and Field Trip are developing second-generation psychedelic drugs that have modified duration times in an effort to condense therapy into a two-hour window. Field Trip Health, a Toronto-based mental health clinic company that has eight ketamine-assisted therapy treatment centers across the U.S. and Canada, also has big plans to bring modified psychedelic molecules to market. Field Trip is developing a psychedelic molecule that targets the 5HT-2A receptor in the brain, the same one psilocybin targets, and plans to pursue FDA approval. The compound, which the company has named FT-104 for the time being, packs a trip that’s only two hours long, or half the time an experience with magic mushrooms lasts. The company plans to launch phase 1 clinical trials early next year. (Not my words)